“The framework to list ultra-expensive new drugs exists"
By Eo, Yun-Ho | translator Alice Kang
21.04.13 13:43:09
가나다라
0
“‘Pre-listing Post-evaluation system’ can be the solution to listing advanced medicines in Korea”
"The basis of the system is ‘evaluation’… how and to whom the system should be applied is important”
“Modifying and utilizing the current system is important… need to consider making adjustments for the new era”
We are living in an era where a single injection may completely cure cancer. The catch is that the 'single dose' would cost 500 million won.
Such ultra-expensive advanced new drugs are not an item of our dreams – it is already within our reach. In addition to the CAR-T (Chimeric Antigen Receptor T cells) therapy Kymriah (tisagenlecleucel) that was approved in Korea, dozens of other gene therapy and cell therapy candidate drugs are also under development, some of which are being developed by domestic biopharmaceutical companies. The regulatory authorities have also passed the ‘Act on Safety and Support for Advanced Regenerative Medicine and Advanced Biopharmaceuticals’ in 2019 to reflect the changes
Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)